Φορτώνει......
An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors
Proteasome inhibitors bortezomib, carfilzomib and ixazomib (approved by the US Food and Drug Administration [FDA]) induce remissions in patients with multiple myeloma (MM), but most patients eventually become resistant. MM and other hematologic malignancies express ubiquitous constitutive proteasome...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Blood Adv |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
American Society of Hematology
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6177641/ https://ncbi.nlm.nih.gov/pubmed/30266819 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018016360 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|